The sale of the activities related to custom contract development and manufacturing of pharmaceutical substances and products is intended to sharpen Merck’s portfolio in line with its medium- to long-term strategic direction and focus it on innovation-driven businesses with high value-creation potential.
The license agreement sees Boehringer pay $358m upfront to cover six biologic preclinical programmes. Sino is also in line for up to $7bn in milestone-based payments, alongside royalties on sales from any drugs commercialised via the partnership.
Through its UK-based investment, which makes up part of its £120m ($161m) investment into the UK life sciences ecosystem, AbbVie will build a new 12,000ft² site dedicated to immunology, neuroscience and oncology research at its existing campus in the South-Eastern British city of Oxford – significantly expanding its research capabilities in the region.
In a recent S-1 filing with the US Securities and Exchange Commission (SEC), Anthropic laid out its intentions to roll out an AI technology it says can “compress decades of scientific progress into years, accelerating drug discovery, disease detection and the delivery of personalised therapy”.
Through RFK Jr’s Enforcement Discretion Policy, pharmacists, licensed physicians or outsourcing facilities under the direction of a licensed pharmacist will now be able to use six active peptide bulk drug substances when creating compounded drugs – despite none of them having secured a regulatory greenlight from the US Food and Drug Administration (FDA).
